Similar to the aforementioned contents, Smad4 is lowly expressed in CHF patients and CH model animals, while its upregulation can inhibit the progression of CHF and CH, which in turn can attenuate the progression of myocardial fibrosis (Wang et al., 2022). Here, SMAD4 is linked to congestive heart failure.